6EW3 image
Entry Detail
PDB ID:
6EW3
Keywords:
Title:
Crystal structure of the metallo-beta-lactamase VIM-2 with ML302F
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2017-11-03
Release Date:
2018-10-03
Method Details:
Experimental Method:
Resolution:
2.14 Å
R-Value Free:
0.20
R-Value Work:
0.16
R-Value Observed:
0.17
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Metallo-beta-lactamase VIM-2
Chain IDs:A, B
Chain Length:232
Number of Molecules:2
Biological Source:Pseudomonas aeruginosa
Primary Citation
Structure activity relationship studies on rhodanines and derived enethiol inhibitors of metallo-beta-lactamases.
Bioorg. Med. Chem. 26 2928 2936 (2018)
PMID: 29655609 DOI: 10.1016/j.bmc.2018.02.043

Abstact

Metallo-β-lactamases (MBLs) enable bacterial resistance to almost all classes of β-lactam antibiotics. We report studies on enethiol containing MBL inhibitors, which were prepared by rhodanine hydrolysis. The enethiols inhibit MBLs from different subclasses. Crystallographic analyses reveal that the enethiol sulphur displaces the di-Zn(II) ion bridging 'hydrolytic' water. In some, but not all, cases biophysical analyses provide evidence that rhodanine/enethiol inhibition involves formation of a ternary MBL enethiol rhodanine complex. The results demonstrate how low molecular weight active site Zn(II) chelating compounds can inhibit a range of clinically relevant MBLs and provide additional evidence for the potential of rhodanines to be hydrolysed to potent inhibitors of MBL protein fold and, maybe, other metallo-enzymes, perhaps contributing to the complex biological effects of rhodanines. The results imply that any medicinal chemistry studies employing rhodanines (and related scaffolds) as inhibitors should as a matter of course include testing of their hydrolysis products.

Legend

Protein

Chemical

Disease

Primary Citation of related structures